Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339, 116th Congress)

Policy Details

Policy Details

Originating Entity
Last Action
Referred to Committee
Date of Last Action
Apr 18 2019
Congressional Session
116th Congress
Date Introduced
Apr 18 2019
Publication Date
May 6 2019

SciPol Summary

The Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339, 116th Congress) would impose additional restrictions, carried out by the Food and Drug Association (FDA) and the Federal Trade Commission (FTC), in an attempt to reduce the rate of youth tobacco use. Specifically, the Act would require:

  • The FDA to issue a final rule to put color, graphic warnings depicting the health consequences of smoking on cigarettes;
  • The FDA to apply stricter labeling and advertising requirements to all tobacco products covered under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 387a);
  •  Raising the age at which entities may sell tobacco products to an individual from 18 to 21;
  • Banning sale of any tobacco product not done through a “direct, face-to-face exchange between a retailer and a consumer”;
  • Banning tobacco products containing artificial or natural flavors other than tobacco with an exception granted to those products that are determined by the FDA to promote smoking cessation among ongoing tobacco users and found to not increase the likelihood of attracting new tobacco users;
  • Increasing user fees of tobacco products;
  • The FDA to issue a final rule to regulate synthetic nicotine;
  • The FTC to regulate the marketing, advertising, or promoting of e-cigarettes to those under 21 years of age, including overseeing enforcement of violations to these provisions; and
  • The FTC to provide a report to Congress detailing advertising and marketing practices by manufacturers of tobacco products including cigarettes, cigars, smokeless tobacco, and e-cigarettes.
SciPol Summary authored by